Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2006 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 19 | 380 | N/A | N/A |
| Receivables | N/A | 473 | N/A | N/A |
| TOTAL | $35 | $1,252 | $N/A | $N/A |
| Non-Current Assets | ||||
| Other Non-Current Assets | 3 | 1,595 | 0 | 0 |
| TOTAL | $3 | $1,595 | $N/A | $N/A |
| Total Assets | $38 | $2,846 | $N/A | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,002 | 954 | 0 | 0 |
| Accrued Expenses | 1,724 | 2,174 | N/A | N/A |
| TOTAL | $4,253 | $3,624 | $N/A | $N/A |
| Non-Current Liabilities | ||||
| Deferred Revenues | 1,429 | 262 | N/A | N/A |
| Other Non-Current Liabilities | 275 | 0 | 0 | 0 |
| TOTAL | $275 | $N/A | $N/A | $N/A |
| Total Liabilities | $4,528 | $3,624 | $N/A | $N/A |
| Shareholders' Equity | ||||
| Common Shares | 8 | 8 | N/A | N/A |
| Retained earnings | -12,184 | -6,461 | N/A | N/A |
| TOTAL | $-4,490 | $-778 | $N/A | $N/A |
| Total Liabilities And Equity | $38 | $2,846 | $0 | $0 |